357 related articles for article (PubMed ID: 7882445)
1. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
2. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
Mann K; Saller B; Mehl U; Hörmann R; Moser E
Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
4. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
[TBL] [Abstract][Full Text] [Related]
5. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
6. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
[TBL] [Abstract][Full Text] [Related]
8. Thyroid-hormone therapy and thyroid cancer: a reassessment.
Biondi B; Filetti S; Schlumberger M
Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):32-40. PubMed ID: 16929364
[TBL] [Abstract][Full Text] [Related]
9. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
10. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
11. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of a sensitive thyrotrophin assay in the fine adjustment of thyroxine therapy following ablation for carcinoma.
de Lange WE; Sluiter WJ; Doorenbos H
Neth J Med; 1989 Aug; 35(1-2):11-7. PubMed ID: 2779691
[TBL] [Abstract][Full Text] [Related]
13. Role of 131I in the treatment of well differentiated thyroid cancer.
Woodrum DT; Gauger PG
J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status.
Schlumberger MJ
J Endocrinol Invest; 1999; 22(11 Suppl):3-7. PubMed ID: 10726999
[TBL] [Abstract][Full Text] [Related]
15. [Response of thyroglobulin, anti-thyroglobulin antibodies, TSH, FT4 and total T3 after rhTSH stimulation in differentiated thyroid carcinoma].
Moreno Ortega E; Vallejo Casas JA; Mena Bares LM; del Real Núñez R; Maza Muret FR; Hidalgo Ramos FJ; Latre Romero JM
Rev Esp Med Nucl; 2008; 27(4):253-8. PubMed ID: 18682151
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
18. Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma.
Hilts SV; Hellman D; Anderson J; Woolfenden J; Van Antwerp J; Patton D
J Nucl Med; 1979 Sep; 20(9):928-32. PubMed ID: 536837
[TBL] [Abstract][Full Text] [Related]
19. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
20. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
